ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1806

Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road

Ertugrul Cagri Bolek, Alper Sari, Levent Kilic, Ali Akdogan, Meryem Asli Tuncer and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, Neurologic involvement and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Spinal cord involvement may occur in the course Behcet’s Disease (BD). It may present with distinct manifestations such as sphincter and/or sexual dysfunction. We aimed to investigate the frequency and clinical features of spinal cord involvement of BD in our Hacettepe University Vasculitis Center (HUVAC) cohort.

Methods: Patients enrolled in prospective HUVAC database were searched in terms of spinal cord involvement of BD. Of 1585 patients recorded since October 2014, 419 patients were BD patients (329 complete and 90 incomplete for ISG Criteria), and 77 (18.4%) of them had NBD (61 definite, 16 possible) according to International Consensus Recommendations (ICR). Spinal cord involvement was diagnosed with neurological examination and spinal magnetic resonance imaging  (MRI). Demographics, clinical features and treatment characteristics of patients were evaluated.

Results: Fifty two (12.4%) patients had parenchymal central nervous system involvement (CNS) whereas 12 (2.8%) had spinal cord involvement. The mean age at diagnosis was not different for spinal with  pNBD and spinal without  pNBD (24.9 ± 5.4 vs. 29.2 ± 9.24, p=0.22). Median time period between diagnosis of BD and NBD is 5.29 years (IQR=9.95).

Detailed clinical features of BD patients with spinal cord involvement were summarized in Table. Three patients had total atrophy of spinal cord. Servical and/or thoracic segments of spinal cord was predominantly involved. Twenty five percent of spinal with pNBD had only one attack of NBD. Corticosteroids (IV pulse = 37/49, 75.5% and oral maintenance =45/50, 90%), interferon (40/52 79%) and cyclophosphamide (28/49, 57.1%) were the most frequently preferred treatment regimens for parenchymal NBD. Over half of them had more than one attack. Almost all had sphincter dysfunction.  One third of patients had deceased.

Conclusion: Spinal cord involvement is very rare in BD. However, it has a big impact on morbidity and mortality of BD patients. Awareness, early diagnosis and recent effective biologic agents might decrease this dramatic scenario.


Disclosure: E. C. Bolek, None; A. Sari, None; L. Kilic, None; A. Akdogan, None; M. A. Tuncer, None; O. Karadag, None.

To cite this abstract in AMA style:

Bolek EC, Sari A, Kilic L, Akdogan A, Tuncer MA, Karadag O. Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/spinal-cord-involvement-in-behcets-disease-experience-of-a-vasculitis-centre-at-silk-road/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spinal-cord-involvement-in-behcets-disease-experience-of-a-vasculitis-centre-at-silk-road/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology